Zeke Capital Advisors LLC acquired a new stake in shares of PerkinElmer, Inc. (NYSE:PKI) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 8,619 shares of the medical research company’s stock, valued at approximately $630,000.
Several other large investors have also recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its position in shares of PerkinElmer by 2.8% in the third quarter. Nationwide Fund Advisors now owns 31,430 shares of the medical research company’s stock valued at $2,168,000 after purchasing an additional 851 shares during the period. State of Wisconsin Investment Board bought a new position in shares of PerkinElmer in the third quarter valued at approximately $1,673,000. Prudential Financial Inc. raised its position in shares of PerkinElmer by 6.1% in the third quarter. Prudential Financial Inc. now owns 161,133 shares of the medical research company’s stock valued at $11,114,000 after purchasing an additional 9,250 shares during the period. Swiss National Bank raised its position in shares of PerkinElmer by 0.8% in the third quarter. Swiss National Bank now owns 184,000 shares of the medical research company’s stock valued at $12,690,000 after purchasing an additional 1,500 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in shares of PerkinElmer by 59.9% in the third quarter. BNP Paribas Arbitrage SA now owns 60,638 shares of the medical research company’s stock valued at $4,182,000 after purchasing an additional 22,710 shares during the period. 91.94% of the stock is currently owned by institutional investors.
A number of equities analysts have recently commented on PKI shares. Robert W. Baird reissued a “buy” rating and issued a $88.00 price target on shares of PerkinElmer in a research report on Friday, January 26th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research report on Monday, January 8th. Cowen reissued a “hold” rating and issued a $84.00 price target on shares of PerkinElmer in a research report on Friday, January 26th. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Evercore ISI started coverage on shares of PerkinElmer in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. PerkinElmer presently has a consensus rating of “Hold” and an average price target of $76.85.
Shares of PerkinElmer, Inc. (PKI) opened at $77.34 on Friday. The stock has a market cap of $8,546.38, a price-to-earnings ratio of 26.49, a PEG ratio of 1.79 and a beta of 0.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.26 and a quick ratio of 0.89. PerkinElmer, Inc. has a 52 week low of $56.07 and a 52 week high of $84.49.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.03. The business had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. PerkinElmer’s quarterly revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the company posted $0.83 earnings per share. research analysts expect that PerkinElmer, Inc. will post 3.52 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 annualized dividend and a dividend yield of 0.36%. PerkinElmer’s payout ratio is 10.61%.
In other news, insider Frank Anders Wilson sold 103,656 shares of the firm’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $73.94, for a total value of $7,664,324.64. Following the sale, the insider now owns 93,624 shares in the company, valued at $6,922,558.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Andrew Okun sold 2,273 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $77.86, for a total transaction of $176,975.78. The disclosure for this sale can be found here. In the last 90 days, insiders sold 108,253 shares of company stock worth $8,016,623. 2.20% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “8,619 Shares in PerkinElmer, Inc. (PKI) Acquired by Zeke Capital Advisors LLC” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/03/18/8619-shares-in-perkinelmer-inc-pki-acquired-by-zeke-capital-advisors-llc.html.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.